KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Assets Average (2021 - 2025)

Historic Assets Average for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Q3 2025 value amounting to $1.4 billion.

  • Recursion Pharmaceuticals' Assets Average rose 7984.24% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 7984.24%. This contributed to the annual value of $1.1 billion for FY2024, which is 5515.26% up from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Assets Average stood at $1.4 billion, which was up 7984.24% from $1.3 billion recorded in Q2 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Assets Average peaked at $1.4 billion during Q1 2025, and registered a low of $285.3 million during Q1 2021.
  • Moreover, its 5-year median value for Assets Average was $664.3 million (2023), whereas its average is $763.3 million.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Assets Average skyrocketed by 13568.76% in 2022, and later crashed by 881.4% in 2024.
  • Recursion Pharmaceuticals' Assets Average (Quarter) stood at $634.5 million in 2021, then grew by 3.46% to $656.4 million in 2022, then dropped by 2.16% to $642.3 million in 2023, then surged by 69.33% to $1.1 billion in 2024, then increased by 24.22% to $1.4 billion in 2025.
  • Its last three reported values are $1.4 billion in Q3 2025, $1.3 billion for Q2 2025, and $1.4 billion during Q1 2025.